Leptin, not adiponectin, predicts hypertension in the copenhagen city heart study

American Journal of Hypertension

Volumn 23, Issue 3, 2010, Pages 327-333

  Asferg, Camilla ^a   Møgelvang, Rasmus ^b   Flyvbjerg, Allan ^c,d   Frystyk, Jan ^c,d   Jensen, Jan S ^b,e   Marott, Jacob L ^a   Appleyard, Merete ^a   Jensen, Gorm B ^a,e   Jeppesen, Jørgen ^a,e  

^a Mental Health Center Glostrup   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adiponectin; Blood pressure; Hypertension; Leptin; Obesity; Overweight; Prospective

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; DENMARK; FEMALE; HUMANS; HYPERTENSION; LEPTIN; MALE; MIDDLE AGED; PROGNOSIS;

EID: 76749161357     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.244     Document Type: Article

References (31)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
2. Bogaert YE, Linas S. The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2009; 5:101-111.
3. Kurukulasuriya LR, Stas S, Lastra G, Manrique C, Sowers JR. Hypertension in obesity. Endocrinol Metab Clin North Am 2008; 37:647-62, ix.
4. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93:S64-S73.
5. Martin SS, Qasim A, Reilly M P. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52:1201-1210.
6. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008; 51:8-14.
7. Qasim A, Mehta NN, Tadesse MG, Wolfe ML, Rhodes T, Girman C, Reilly M P. Adipokines, insulin resistance, and coronary artery calcification. J Am Coll Cardiol 2008; 52:231-236.
8. Galletti F, D'Elia L, Barba G, Siani A, Cappuccio F P, Farinaro E, Iacone R, Russo O, De Palma D, Ippolito R, Strazzullo P. High-circulating leptin levels are associated with greater risk of hypertension in men independently of body mass and insulin resistance: results of an eight-year follow-up study. J Clin Endocrinol Metab 2008; 93:3922-3926.
9. Franks PW, Brage S, Luan J, Ekelund U, Rahman M, Farooqi IS, Halsall I, O'Rahilly S, Wareham NJ. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005; 13:1476-1484.
10. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007; 49:1455-1461.
11. Imatoh T, Miyazaki M, Momose Y, Tanihara S, Une H. Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res 2008; 31:229-233.
12. Appelyard M, Jensen G, Scharling H, Schnohr P. The Copenhagen City Heart Study. Osterbroundersogelsen. A book of tables with data from the first examination (1976-1978) and a five year follow-up (1981-83). The Copenhagen City Heart Study Group. Scand J Soc Med Suppl 1989; 41:1-160.
13. Schnohr P, Jensen G, lange P, Scharling H, Appelyard M. The Copenhagen City Heart Study. Østerbroundersøgelsen. Tables with data from the third examination. Eur Heart J Suppl H 2002; 3:H1-H83.
14. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483.
15. Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci USA 2004; 101:10434-10439.
16. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005; 48:1911-1918. (Pubitemid 41317848)
17. Parikh NI, Pencina MJ, Wang TJ, Benjamin EJ, Lanier KJ, Levy D, D'Agostino RB Sr, Kannel WB, Vasan RS. A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med 2008; 148:102-110.
18. Sabatier MJ, McCully KK, Marinik EL, Schwark EH, Haddow S, Cortez-Cooper M, Bergeron MF, Sloan GJ, Cannon JG. Leptin, blood pressure, and aerobic capacity in women. Am J Hypertens 2008; 21:1245-1250.
19. Jeppesen J. Triglycerides, high-density lipoprotein cholesterol, and risk of ischemic heart disease: a view from the Copenhagen Male Study. Metab Syndr Relat Disord 2003; 1:33-53.
20. Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad MF, Rotter JI, Guo X, Chen YD, Bryer-Ash M, Norris JM, Haffner SM. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 2007; 92:2665-2671.
21. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730-1737.
22. Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 2008; 93:3299-3301.
23. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006; 114:623-629.
24. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112:1756-1762.
25. Pilz S, Mangge H, Wellnitz B, Seelhorst U, Winkelmann BR, Tiran B, Boehm BO, März W. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006; 91:4277-4286.
26. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17:2599-2606. (Pubitemid 44300977)
27. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab 2008; 93:3357-3364.
28. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002; 23:620-626.
29. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001; 14:103S-115S.
30. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45:9-14.
31. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006; 24:789-801.